CoChat

Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options

Gronda, Edoardo, Vanoli, Emilio, Sacchi, Stefania, Grassi, Guido, Ambrosio, Giuseppe, Napoli, Claudio · 2020 · Heart Failure Reviews

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Transition from stage C to stage D of heart failure (HF) represents an irreversible process toward end-stage disease. Crucial interventions to be adopted in the attempt to interfere with this process are represented by the identification of patients at high risk to develop HF progression and by an effective and prompt management. Markers of worse prognosis and disease progression are well established and include recurrence of HF decompensation, intolerance to the neurohormonal standard pharmacological treatment, and resistance to loop diuretics. In addition, both NT-proBNP and sympathetic nervous system (SNS) overdrive are strong predictors of adverse clinical outcome and allow to identify high-risk HF patients even in the presence of mild symptoms. To counteract the deleterious effects of the SNS activation, new strategies such as a new drug combining angiotensin receptor and neprilysin inhibition and baroreceptor stimulation therapy (BAT) have been investigated. Inability to properly counteract the SNS overdrive leads to acute HF decompensation by different mechanisms. The leading ones are represented by the progressive sodium and water retention with fluid overload and by the blood volume redistribution between splanchnic and non-splanchnic regions. The correct understanding of these mechanisms, together with the availability of new therapeutic options such as peritoneal ultrafiltration, represent the rationale but not infrequently overlooked therapeutic options to improve congestion management in HF patients.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10741-019-09823-z

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Cited by

See all 31

Metadata

Authors
Gronda, E., Vanoli, E., Sacchi, S., Grassi, G., Ambrosio, G., & Napoli, C.
Affiliations
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
  • University of Pavia (IT)
  • University of Milano-Bicocca (IT)
  • University of Perugia (IT)
Corresponding author
Gronda, Edoardo
Venue
Heart Failure Reviews
Published
2019-08-13
Volume
25
Issue
2
Pages
295-303
ISSN
  • 1382-4147 (ISSN-L)
  • 1573-7322
OpenAlex
W2967206555
Cited by
30
References
64
Citations by year
2025: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 9 · 2019: 1
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Heart Failure Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
heart failure progression, reduced ejection fraction, heart failure decompensation, NT-proBNP, angiotensin receptor-neprilysin inhibition, loop diuretic resistance, fluid overload, sodium and water retention, blood volume redistribution, peritoneal ultrafiltration, congestion management, end-stage heart failure, prognostic factors
MeSH terms
Heart Failure, Humans, Peptide Fragments, Risk Factors, Stroke Volume, Biomarkers, Disease Progression, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. https://app.cochat.ai/papers/10.1007/s10741-019-09823-z
The paper
Gronda, E., Vanoli, E., Sacchi, S., Grassi, G., Ambrosio, G., & Napoli, C. (2020). Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Failure Reviews. https://doi.org/10.1007/s10741-019-09823-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.